|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
90,552,000 |
Market
Cap: |
3.34(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$18.07 - $44.07 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : 8 |
Insider 3/6 Months : 8.6 |
|
Guru Rank Number : 538 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile PTC Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. Co. has the following products, Translarna (ataluren) and Emflaza® (deflazacort), for the treatment of Duchenne muscular dystrophy, a rare, life threatening disorder. Co.'s gene therapy product candidates for rare monogenic diseases that affect the central nervous system (CNS) include PTC- Aromatic L-Amino Acid Decarboxylase (AADC) for the treatment of AADC deficiency, a rare CNS disorder arising from reductions in the enzyme AADC that results from mutations in the dopa decarboxylase gene.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
7,700 |
7,700 |
7,700 |
Total Buy Value |
$0 |
$198,736 |
$198,736 |
$198,736 |
Total People Bought |
0 |
1 |
1 |
1 |
Total Buy Transactions |
0 |
1 |
1 |
1 |
Total Shares Sold |
26,156 |
72,347 |
85,013 |
300,515 |
Total Sell Value |
$921,768 |
$2,218,045 |
$2,727,877 |
$13,658,321 |
Total People Sold |
4 |
9 |
10 |
16 |
Total Sell Transactions |
6 |
28 |
30 |
90 |
End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Almstead Neil Gregory |
CHIEF TECHNICAL OPS OFFICER |
|
2023-01-10 |
4 |
S |
$42.93 |
$1,159 |
I/I |
(27) |
3,358 |
|
-32% |
|
Almstead Neil Gregory |
CHIEF TECHNICAL OPS OFFICER |
|
2023-01-10 |
4 |
S |
$42.93 |
$20,307 |
D/D |
(473) |
64,962 |
|
-32% |
|
Hill Emily Luisa |
CHIEF FINANCIAL OFFICER |
|
2023-01-10 |
4 |
S |
$42.93 |
$21,338 |
D/D |
(497) |
47,504 |
|
-32% |
|
Utter Christine Marie |
SVP, FINANCE & CAO |
|
2023-01-10 |
4 |
S |
$42.93 |
$20,994 |
D/D |
(489) |
38,801 |
|
-32% |
|
Boulding Mark Elliott |
EXEC. VP AND CLO |
|
2023-01-10 |
4 |
S |
$42.93 |
$25,330 |
D/D |
(590) |
76,685 |
|
-32% |
|
Pauwels Eric |
CHIEF BUSINESS OFFICER |
|
2023-01-10 |
4 |
S |
$42.93 |
$28,465 |
D/D |
(663) |
66,842 |
|
-32% |
|
Peltz Stuart Walter |
CHIEF EXECUTIVE OFFICER |
|
2023-01-10 |
4 |
S |
$42.93 |
$24,515 |
I/I |
(571) |
55,980 |
|
-32% |
|
Peltz Stuart Walter |
CHIEF EXECUTIVE OFFICER |
|
2023-01-10 |
4 |
S |
$42.93 |
$52,722 |
D/D |
(1,228) |
170,471 |
|
-32% |
|
Hill Emily Luisa |
CHIEF FINANCIAL OFFICER |
|
2023-01-09 |
4 |
S |
$41.66 |
$31,575 |
D/D |
(758) |
48,001 |
|
-40% |
|
Klein Matthew B. |
CHIEF OPERATING OFFICER |
|
2023-01-09 |
4 |
S |
$41.66 |
$30,451 |
D/D |
(731) |
82,373 |
|
-40% |
|
Pauwels Eric |
CHIEF BUSINESS OFFICER |
|
2023-01-09 |
4 |
S |
$41.66 |
$35,741 |
D/D |
(858) |
67,505 |
|
-40% |
|
Utter Christine Marie |
SVP, FINANCE & CAO |
|
2023-01-09 |
4 |
S |
$41.66 |
$29,409 |
D/D |
(706) |
39,290 |
|
-40% |
|
Peltz Stuart Walter |
CHIEF EXECUTIVE OFFICER |
|
2023-01-09 |
4 |
S |
$41.66 |
$11,622 |
I/I |
(279) |
56,551 |
|
-40% |
|
Peltz Stuart Walter |
CHIEF EXECUTIVE OFFICER |
|
2023-01-09 |
4 |
S |
$41.66 |
$74,398 |
D/D |
(1,786) |
171,699 |
|
-40% |
|
Boulding Mark Elliott |
EXEC. VP AND CLO |
|
2023-01-09 |
4 |
S |
$41.66 |
$34,783 |
D/D |
(835) |
77,275 |
|
-40% |
|
Almstead Neil Gregory |
CHIEF TECHNICAL OPS OFFICER |
|
2023-01-09 |
4 |
S |
$41.66 |
$1,791 |
I/I |
(43) |
3,385 |
|
-40% |
|
Almstead Neil Gregory |
CHIEF TECHNICAL OPS OFFICER |
|
2023-01-09 |
4 |
S |
$41.66 |
$29,826 |
D/D |
(716) |
65,435 |
|
-40% |
|
Peltz Stuart Walter |
CHIEF EXECUTIVE OFFICER |
|
2023-01-05 |
4 |
A |
$0.00 |
$0 |
I/I |
18,000 |
56,830 |
|
- |
|
Peltz Stuart Walter |
CHIEF EXECUTIVE OFFICER |
|
2023-01-05 |
4 |
A |
$0.00 |
$0 |
D/D |
53,000 |
173,485 |
|
- |
|
Utter Christine Marie |
SVP, FINANCE & CAO |
|
2023-01-05 |
4 |
A |
$0.00 |
$0 |
D/D |
14,000 |
39,996 |
|
- |
|
Steele Glenn Jr Md |
|
|
2023-01-05 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
10,500 |
|
- |
|
Zeldis Jerome B |
|
|
2023-01-05 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
10,500 |
|
- |
|
Young Alethia |
|
|
2023-01-05 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
9,067 |
|
- |
|
Jacobson Allan Steven |
|
|
2023-01-05 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
12,348 |
|
- |
|
Reeve Emma |
|
|
2023-01-05 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
11,528 |
|
- |
|
524 Records found
|
|
Page 5 of 21 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|